The purpose of this study was to assess the role of ABMT in children with ALL who are in 2nd CR after an early isolated CNS relapse. All children experiencing an isolated CNS relapse at 10 AIEOP centers (Associazione Italiana Emato-Oncologia Pediatrica) from 1986 to 1992 were eligible for this study. The series included 69 patients who relapsed within 3 years from diagnosis: 19 underwent ABMT, nine patients underwent ALLO-BMT from an HLA-identical sibling, and 41 received conventional chemotherapy (CHEMO). Statistical analysis was performed using a Cox's regression model, adjusting for the waiting time before transplantation and prognostic factors. The 5 years DFS was 56.3% (s.e. 12.3) for patients in the ABMT group. This compared favorably with the poor result (12.6% (s.e. 5.9) ) seen in the CHEMO group. The risk of failures was reduced by one-third in the ABMT group as compared to the CHEMO group in the multivariate analysis (P Ͻ 0.01). In the ALLO group four out of nine patients were in CCR 4-5 years post-transplant. This study suggests that ABMT may also represent a valuable therapeutic choice for patients lacking a matched familiar donor in 2nd CR after an early isolated CNS relapse. Keywords: childhood lymphoblastic leukemia; meningeal relapse; autologous marrow transplantation Isolated CNS relapse occurs in 5-10% of children with ALL treated with risk-directed therapy.
survival. 3 Retreatment induces a second CR but due to further relapses the event-free-survival (EFS) is in the 20-30% range, with few exceptions. [2] [3] [4] [5] [6] [7] [8] Successful treatment of CNS relapse must include CNS-directed and intensive systemic therapy. Major CNS problems have been described in long-term survivors after conventional retreatment. 9 The role of BMT in the therapeutic strategy of isolated CNS relapse has only recently been explored, with controversial results. 7, [10] [11] [12] Our study investigates the role of ABMT in a relatively large series of 60 children with ALL, who developed a first isolated CNS relapse early, ie within 3 years of diagnosis. Of these, 19 underwent ABMT, while 41 had chemotherapy only; we also include our limited experience on nine patients who had ALLO-BMT. This retrospective study has been based on the experience of all the AIEOP centers that considered ABMT as a therapeutic option for ALL children after an isolated CNS relapse from 1986 to 1992. The analytical method adopted here aimed to exclude any biases related to the retrospective nature of the study and the waiting time before transplantation.
Patients and methods

Patients
CNS relapse was defined as the presence in the cerebrospinal fluid of Ͼ5 mononuclear cells per microliter, morphologically identified as lymphoblasts on cytospinning. ABMT and, to a lesser degree, also ALLO-BMT, have been considered as a therapeutic option after an isolated CNS relapse at 10 AIEOP transplantation centers since 1986. From 1986 to 1993, 20 consecutive children underwent ABMT in 2nd CR. In 19 of these, the relapse had occurred at a median of 23 months (range 4-33) after 1st CR. The remaining patient had his first CNS relapse 69 months after 1st CR, and underwent ABMT 4.5 months after 2nd CR: he is still in CR 30 months later. He was not included in the present study, as it was restricted to 'early' relapses. Nine children underwent ALLO-BMT in 2nd CR after an isolated CNS relapse. For these patients, the median duration of 1st CR was 20 months (range 6-27). Overall, the transplanted patients had experienced their first CNS relapse from March 1986 to August 1992, and had achieved a second remission an average of 3 weeks later (range 1-10). These patients were transplanted at a median of 5 months (range 1-17) after achieving a second CR. To obtain a control group of untransplanted patients, we reviewed the records of all children with ALL undergoing the same AIEOP front-line therapies at the same 10 centers. A series of 41 children was identified who had an isolated CNS relapse in the same calendar period as the transplanted series, and had not undergone transplantation in 2nd CR. For these conventionally treated patients, the median duration of the first remission was 18 months (range 3-35). The patients' characteristics (age, WBC and immunophenotype at diagnosis, sex, duration of first CR) are shown in Table 1 . Results are as of 31 March 1997.
Front-line treatment
The front-line treatment was administered according to the AIEOP co-operative protocol adopted at the time of diagnosis. Thus, the treatment protocols that were applied throughout the period considered here were part of the studies AIEOP ALL 82, 87 based on the Children's Cancer Study Group, [13] [14] [15] and AIEOP ALL 88, based on the BFM stratification and treatment criteria, 16 respectively. Stratification into standard, average, and high-risk groups at diagnosis depended mainly on age and WBC counts (study 82, 87) or the BFM risk index (study 88). Details of the treat- ments have been reported elsewhere. [13] [14] [15] [16] The summary of CNS prophylaxis is reported on Table 2 .
Relapse treatment
Eighteen patients received two courses of L-VAMP regimen (day 1 VCR h 0; HD MTX h 1-3; Ara-C h 3-7; L-ASI 24 h post-MTX; PDN for 14 days). Sequential systemic maintenance therapy consisted of four rotating drug pairs (6-thioguanine/cyclophosphamide, hydroxyurea/daunomycin, MTX/BCNU, Ara-C/VCR) until the completion of 30 months of treatment. Twenty-six patients were treated according to a modified version of the BFM relapse protocol without cranial irradiation. 17 Twelve patients received systemic therapy according to the high-risk protocol of the following AIEOP protocol generation (Prot 8703; Table 2 Summary of CNS prophylaxis in the front-line treatment 8803). 14, 16 Thirteen children were treated according to the ALL R-87 protocol, previously reported, until they had completed 2 years of retreatment. 18 CNS-directed therapy consisted of 24 Gy cranial, 10 Gy spinal irradiation in 11 patients who did not undergo transplantation. For the remaining patients in the CHEMO group, CNS-directed therapy included 6 weekly TIT injections, followed by 6 TIT every 4 weeks, then by TIT every 8 weeks until the completion of 24-30 months of retreatment. The patients who underwent either ABMT or ALLO-BMT received 6 weekly TIT injections before conditioning. As shown in Table 3 , 24 of 28 patients adopted a conditioning regimen including TBI. No radiotherapy boost to CNS was added to TBI and no intrathecal therapy was administered after transplantation.
Transplant-related mortality (TRM) was defined as death occurring during the first 100 days after BMT due to causes other than leukemia.
Statistical analysis
DFS considered either relapse (at any site) or death in the second remission as a failure, and survival considered death alone (whatever the cause). Follow-up was updated as of March 1997 and thus the potential follow-up ranged from a minimum of 4 years to a maximum of 10 years from 2nd CR. The standard Kaplan-Meier curves were plotted for the entire series, while the graphical representation of the DFS curves by treatment group was adjusted to account for the median waiting time before transplantation. 19 In particular, events which occurred before a certain landmark point (in this case the median time to BMT) were not considered in the CHEMO group. Accordingly, in order to avoid the time-to-transplant bias, the difference between the DFS of untransplanted and transplanted patients was tested by applying a Cox's model 20 with the DFS calculated for all patients from the date of the second CR and with a timedependent indicator that expresses transplantation status. 21 This analysis allows comparison of patients who are 'at risk' in the two groups at equal times from CR. Pointwise confidence intervals for DFS probability were estimated according to Greenwood and relied on the normal approximation. The estimation of the effect of treatment was adjusted by a restricted set of covariates indicating duration of first remission, age and WBC count at diagnosis, immunophenotype and sex. A step-down procedure was also Table 3 Conditioning regimens Ara-C/TBI 14. adopted to select the covariates of prognostic value (at the alpha = 0.05 level according to the Wald statistic). The cumulative incidence of relapse was estimated accounting for the competing risk of death in CR. 21 The SAS package (PHREG procedure and ad hoc Macros) was used to perform the analysis.
Results
The 5-year figures for overall DFS and survival were 27.7 (s.e. 5.5) and 38.9 (s.e. 6), and the 8-year figures were 25.0 (s.e. 5.6) and 33.0 (s.e. 6.4) for DFS and survival, respectively. In the ABMT group, three patients died within 1 month of the BMT due to sepsis during the aplastic phase, leading to a 16% TRM. The 2-year cumulative incidence of relapse was 21.1% (s.e. 9.4) and four of the five relapses occurred within 1 year of ABMT involving the marrow. Leukemia recurrence was followed by death in three patients (who died 1, 2 and 15 months after relapse). In the CHEMO group, five patients (12%) died in remission after a median of 8 months (range 1-28) of second CR due to infection (n = 2), multiorgan toxicity (n = 2), or degenerative neuropathy (n = 1). In the CHEMO group, 32 relapses were observed, all but one within 4 years of the second CR, and the estimated 2-year and 4-year cumulative incidence of relapse was 52.4% (s.e. 7.9) and 77.5% (s.e. 7.9), respectively. Relapses involved the bone marrow in 16 cases, the CNS in 14, the testes in one, and the optic nerve in one.
In the ALLO-BMT group, 3/9 patients died within 3 months of BMT due to aGVHD (n = 2) or ARDS (n = 1). One patient suffered a bone marrow relapse 4 months after transplantation and died. A thyroid carcinoma was diagnosed in one patient 4 years after transplantation (and 5.1 years after the diagnosis of ALL). The remaining four patients who underwent ALLO-BMT were alive and well about 4 years (n = 3) and 5.5 years (n = 1) after BMT.
The adjusted DFS curves comparing the outcome in the CHEMO and ABMT groups, plotted in Figure 1 , suggest an advantage of ABMT over CHEMO: the 5-year DFS was 56.3% (s.e. 12.3) and 12.6% (s.e. 5.9), respectively. The test on the effect of treatment, carried out with a Cox's model accounting for time before transplantation, showed a significant advantage of ABMT over CHEMO (P = 0.026), and the estimated hazard ratio of ABMT vs CHEMO was 0.4, with a 95% confidence interval (CI) of 0.2-0.9. When the comparison was adjusted for patient and disease characteristics, as shown in Table 4 , a significant effect of treatment was still obtained, with an estimated hazard ratio of 0.33 (CI 0.1-0.8), indicating that the risk of an unfavorable outcome (relapse or death in second CR) in the ABMT group is about one-third of the risk in the CHEMO group. None of the remaining covariates considered in the model proved significantly related to prognosis. When a step-down procedure was performed, the only other variable included in the final model, in addition to treatment (HR = 0.31, P = 0.01), was the WBC count at diagnosis: higher WBC counts seemed to retain some negative influence on prognosis, with an estimated HR (WBC Ͼ50 000 vs WBC Ͻ50 000) of 1.9 (P = 0.04). 
Discussion
The long-term prognosis of children with ALL who develop a CNS relapse after meningeal prophylaxis has been poor in the majority of series published. 4, 5 Our earlier experience confirmed these findings (data not shown). As of 1986, 10 Italian pediatric centers began considering BMT following a re-induction phase as a therapeutic option after a first isolated CNS relapse. The preliminary results of ABMT have already been reported. 10, 22 However, a thorough analysis of the role of transplantation must include a comparison with results obtained in children treated with chemotherapy alone. Our retrospective study was based on a series of 19 patients who underwent ABMT and 41 controls who were all the patients treated after a first CNS relapse with chemotherapy alone, using the same front-line protocols as the transplanted cases. Our study could have the intrinsic drawbacks of all retrospective evaluations with the lack of any planned and controlled criteria for allocation to treatment. The case control analysis could have been another approach to this type of data. However, due to the relatively small group of patients, we would have had difficulties in selecting one to two controls well matched for each case. It is discussed in the methodological literature that the type of analysis we adopted avoids the major biases.
An interesting feature of our series is that, unlike others, 7 it is relatively homogeneous and characterized by several unfavorable factors, known to be associated with a poor outcome in most studies. 6, 8 In fact, all patients were in second CR after an early CNS relapse and their characteristics at diagnosis (age, WBC count, immunophenotype and sex) had a comparable distribution in the groups. Moreover, 90% of the patients had had prior prophylactic radiotherapy and 50% had received anthracycline therapy. This may explain why we obtained unsatisfactory results in the CHEMO group by comparison with the series described by others. 6, 8 Anyway, our results were consistent with those obtained by the small group of patients with the same unfavorable characteristics described by said authors 6, 8 and by others too. 2, 5 The major criticism that we could raise about the treatment of the CHEMO group is that radiotherapy in the second-line treatment was almost completely avoided in most patients. This strategy took into account that the majority of patients had received prophylactic cranial irradiation and there was a reluctance to re-irradiate the CNS or use craniospinal irradiation. Systemic therapy was adopted using drugs such as high-dose Ara-C, intermediateor high-dose MTX, which are known to penetrate well into the cerebrospinal fluid, inducing remission of meningeal leukemia. 3, 4 The CNS-directed therapy consisted of prolonged TIT injections. Unfortunately, this approach proved unsatisfactory. In fact, 78% of patients experienced a new relapse (50% BM; 50% CNS).
Even the ABMT group showed unfavorable characteristics and predictors of poor outcome such as median duration of 1st CR of 23 months, previous prophylactic radiotherapy in 17 out of 19, anthracycline therapy in 18 of 19 due to the first line protocol. 6, 8 Nevertheless, a cumulative low incidence of relapse (21.1%) was experienced, all but one due to a marrow relapse within 1 year. We highlight that neither cranial boost nor IT therapy were administered post-ABMT. We do not know exactly if TBI played a role in limiting the overall relapse rate but the standard for control of isolated meningeal leukemia (against which other therapies are measured) is 24 Gy cranial or cranio-spinal (24 + 15 Gy) irradiation. 6, 8 One could consider changing strategy and using high-dose chemotherapy only for autograft sparing TBI for a matched unrelated donor transplant in the event of subsequent relapse. However, on the basis of reported experiences, there is no evidence that such an approach would result in a similar outcome to that seen by us.
ABMT could be costly in terms of late toxicities: infertility, growth, thyroid disorders and second malignancies are commonly associated with TBI. Many of these late effects could also affect patients undergoing cranial or cranio-spinal irradiadiation. To date, only one case of second malignancy has been reported in the ALLO-BMT group and no major CNS problems were noted. Prospective clinical and psychological studies are ongoing. On the other hand, intensive chemotherapy may be reasonably attributed a lower, although not absent, treatment-related mortality but effective treatment for these patients involves protracted intensive therapy.
Allogeneic BMT from a matched family donor could be considered a reasonable choice [23] [24] [25] even in isolated CNS relapse 12 although its advantage is not yet clear. The results obtained in our small group of nine ALLO-BMT patients reflected the effects of TRM and, to a lesser extent, relapse. Even in the BFM experience TRM and relapse have been reported to affect the final outcome of allotransplant: of the 17 treated patients, six are in CR, four had an early death and seven relapsed. It seems reasonable that, reducing the TRM, ALLO-BMT could play an important role.
In conclusion, our data show that ABMT has an advantage in terms of DFS compared to chemotherapy and justify it as a valid choice of therapy for patients in second CR after an isolated ALL CNS relapse. We acknowledge that current standard chemotherapy may provide disease control better than we achieved in our complementary group. The choice of which treatment to adopt would require a comparative evaluation of different treatment modalities and a co-operative study could be useful to identify the best option. If results are similar, quality of life should be considered.
